Mark Chin - May 4, 2021 Form 4/A - Amendment Insider Report for Harpoon Therapeutics, Inc. (HARP)

Role
Director
Signature
/s/ Mark Chin by Christopher Whitmore, Attorney-in-Fact
Stock symbol
HARP
Transactions as of
May 4, 2021
Transactions value $
$0
Form type
4/A - Amendment
Date filed
5/14/2021, 07:57 PM
Date Of Original Report
May 7, 2021
Next filing
Jun 25, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HARP Director Stock Option (Right to Buy) Award $0 +10.2K $0.00 10.2K May 4, 2021 Common Stock 10.2K $23.20 Direct F1, F2
transaction HARP Director Stock Option (Right to Buy) Award $0 +2.44K $0.00 2.44K May 4, 2021 Common Stock 2.44K $23.20 Direct F3, F4, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error.
F2 The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022.
F3 This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error related to the calculation date of the Black-Scholes value.
F4 The number of shares underlying the option was erroneously reported as 3,017 on the original Form 4 filed on May 7, 2021 due to an administrative error related to the calculation date of the Black-Scholes value.
F5 50% of the shares subject to the option are fully vested and exercisable, and 25% will vest and become exercisable on September 30, 2021 and December 31, 2021, subject to the continuous service of the Reporting Person on each vesting date.